
$Myc\text{-}Max_70551_lead_inhibitor_development$


April 8, 2022

1 Computational Drug Discovery Pipeline for c-Myc-Max and N-Myc-Max inhibitors of DNA binding and transcriptional activity

Computer-aided drug discovery (CADD)




Myc-Max DNA Binding Site



Carabet LA et al. Computer-aided drug discovery of Myc-Max inhibitors as potential therapeutics for prostate cancer. Eur J Med Chem 2018, 160, 108-119


Myc-Max/DNA 5'-CACGTG-3' interactions



2 Development of 70551 Lead Myc-Max Inhibitor

2.1 Optimization Pathway 70033 -> 70127 -> 70551

70551 Development



Carabet LA. Application of Computer-Aided Drug Discovery Methods for Targeting the Oncogenic Activity of Myc in Prostate Cancer. 2019,

```
PandasTools.AddMoleculeColumnToFrame(df, 'smiles', 'Mol')

df_opt = df.loc[df['id'].isin([70033, 70127, 70545, 70546, 70551])]

df_opt = df_opt.reset_index(drop=True)

mol_list = df_opt["Mol"]

core_smiles = [Chem.MolToSmiles(MurckoScaffold.GetScaffoldForMol(m)) for m in_u

omol_list]

df_opt['core_smiles'] = core_smiles

PandasTools.AddMoleculeColumnToFrame(df_opt, 'core_smiles', 'Scaffold')

df_opt.loc[:, 'IC50 (µM)'] = [10, 1, '', '', 4]

df_opt
```


```
[2]: id smiles \
0 70033 Clc1c(C(F)(F)F)cc([N+](=0)[0-])c(Nc2ccc(NC(=0)...
1 70127 FC(F)(F)c1cc([N+](=0)[0-])c(NNC(=0)c2nccnc2)cc1
2 70545 FC(F)(F)c1cc(C(=0)NNc2c(F)c(F)cc2)ccc1
3 70546 FC(F)(F)c1c(NNC(=0)c2ccc(C(=0)N(C)C)cc2)cccc1
4 70551 FC(F)(F)c1c(NNC(=0)c2ccc(C(F)(F)F)cc2)ccc(C#N)c1

Mol core_smiles \
0 <img data-content="rdkit/molecule" src="data:i... c1ccc(Nc2cccc2)cc1
```

2.1.1 70127 structural analysis, predicted metabolism, and biological profile

70127 distant analog of initial hit 70033 with an novel chemical scaffold resulting from ROCS ligand-based chemical similarity searches


70127



2.1.2 Derivatives of 70127

```
[3]: ids = df_opt["id"].astype({'id': 'string'}).tolist()
    common_scaffold = Chem.MolFromSmiles('O=C(NNC1=CC=CC=C1)C1=CC=CC=C1')
    match_list = [mol.GetSubstructMatch(common_scaffold) for mol in mol_list]
    Draw.MolsToGridImage(mols=mol_list, molsPerRow=2, □
    →highlightAtomLists=match_list, legends=ids)
```


[3]:



70033 70127



70545 70546



70551

2.1.3 Some evidence of SAR for the derivatives of 70127 resulting from substructure searches without the reactive nitro group and replacement of the metabolically vulnerable pyrazine ring

The activities of the three analogs positively correlate with the pharmacophore RMSD values. The lower the RMSD, the higher the activity. 70551 shows best inhibition of Myc-Max transcriptional activity.

```
0 70551 98
1 70545 66
2 70546 58

RMSD pharmacophore (Å)
0 0.60
1 0.98
2 1.23
```

2.1.4 Potency, specificity and number of predicted metabolites comparison between 70127 and 70551

```
[5]: id % Non-specific cytotoxicity # Predicted metabolites 0 70127 19 3 1 70551 10 0
```

2.1.5 70551 lead novel active scaffold


```
[6]: lead_active_scaffold = Chem.


→MolFromSmiles('FC(F)(F)C1=C(NNC(=0)C2=CC=CC)C=CC(=C1)C#N')


match_list = [mol.GetSubstructMatch(lead_active_scaffold) for mol in mol_list]


Draw.MolsToGridImage(mols=mol_list, molsPerRow=2, 
→highlightAtomLists=match_list, legends=ids)
```


[6]:













2.2 Structural determinants of 70551 binding affinity for c-Myc-Max site at the DNA interface and activity in models of castration-resistant prostate cancer (CRPC)




2.3 70551 identical binding affinity for the equivalent N-Myc-Max site at the DNA interface and same activity in models of neuroendocrine prostate cancer (NEPC)



2.4 70551 - moderately potent, specific and metabolically stable, with some evidence of SAR


70551 Lead Inhibitor



Carabet LA. Application of Computer-Aided Drug Discovery Methods for Targeting the Oncogenic Activity of Myc in Prostate Cancer. 2019,

2.5 70551 competes with DNA for binding to Myc-Max dimer by mimicking DNA interactions with specific residues, mutations of which abrogate Myc-Max binding to DNA, matches the pharmacophore/hydrophobic core of the binding site and clashes with DNA

70551 versus DNA 5'-CACGTG-3'



[]: